Effects of coenzyme Q₁₀ supplementation on the serum levels of amylase, adenosine deaminase, catalase, and total antioxidant capacity in women with type 2 diabetes mellitus: A randomized, double-blind placebo-controlled trial

Abstract

Background:Increased levels of reactive oxygen species is a key factor involved in the pathogenesis of type 2 diabetes mellitus (T2DM). Coenzyme Q10 (CoQ10) is a nonenzymatic antioxidant that restores other antioxidants.Materials and Methods:This randomized, double-blind placebo-controlled trial study has been designed to evaluate the effects of CoQ10 supplementation on serum values of amylase, adenosine deaminase, catalase (CAT), total antioxidant capacity (TAC) and the quantitative insulin sensitivity check index (QUICKI) in women with T2DM. Serum levels of CoQ10 were measured too. Sixty-eight women with T2DM were enrolled in this study and randomly divided into two groups. One group received 100 mg/day of CoQ10 supplement for 12 weeks (n = 34), and the other group was given placebo for the same time duration and dosage (n = 34).Results:After the intervention, serum CAT activity (P < 0.001), TAC (P = 0.006), CoQ10 (P = 0.001), and QUICKI (P = 0.005) increased and fasting blood sugar (FBS) (P = 0.05) decreased significantly in CoQ10 group.Conclusion:This study showed that daily supplementation with 100 mg of CoQ10 could increase TAC and CAT activity as, CoQ10 and QUICKI and could reduce oxidative stress and FBS in women with T2DM.

Evaluation of Advanced Glycation End Products, Oxidative Stress and Antioxidants and their Relationship in Diabetic patients

“…These results are consistent with some previous report investigations which exhibited that the serum levels CAT, GSH, SOD, and GSH-Px are lower in DM patients as compared to the control group (Arpaci et al, 2020, Dworzański et al, 2020, Arribas et al, 2016. However, the results of this study are in disagreement with the results of a previous study that demonstrated the CAT level in serum DM patients is significantly higher than in the healthy group (Zarei et al, 2018). Recently similar patterns of data have been obtained, about a decrease in CAT, GSH, SOD, and GSH-Px serum levels in DM patients (Feng et al, 2020, Onyibe et al, 2021, Ling et al, 2020.…”

Coenzyme Q10: A Key Antioxidant in the Management of Diabetes-Induced Cardiovascular Complications—An Overview of Mechanisms and Clinical Evidence

“…Khosrowbeygi et al found that consuming 100 mg/day of CoQ10 raised TAC, catalase activity, and QUICKI, while decreasing oxidative stress and fasting blood sugar (FBS) levels in women with T2DM [54]. Similarly, Hosseinzadeh-Attar et al reported that giving 200 mg/day of CoQ10 to T2DM patients resulted in a substantial decrease in HbA1c levels, indicating better glycemic management.…”

Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview

“…Some 15 randomised controlled clinical trials supplementing CoQ10 (typically 100–200 mg/day for 3–6 months) in type II diabetic patients are currently listed by Medline. Although Eriksson et al [23] found no significant benefit of CoQ10 supplementation on glycaemic control in type II diabetics, subsequent studies reported CoQ10 supplementation significantly improved fasting plasma glucose and HbA1c (glycated haemoglobin )levels [24,25,26,27,28].…”